Mineralys Therapeutics (MLYS) said Monday that lorundrostat met primary endpoints in phase 3 Launch-HTN and phase 2 Advance-HTN trials in patients with uncontrolled hypertension or resistant hypertension.
Shares surged 73% as intraday trading volume soared to more than 12.4 million from a daily average of about 283,000.
Rocket (RKT) said Monday it will buy real-estate brokerage Redfin (RDFN) for an equity value of $1.75 billion to drive users to its home-lending business.
Shares of Redfin soared 65% as intraday trading volume catapulted to more than 81.1 million from a daily average of about 5.5 million.
Protagonist Therapeutics (PTGX) and Johnson & Johnson (JNJ) said a phase 2b study of the investigational targeted oral peptide icotrokinra in adults with moderately to severely active ulcerative colitis met the primary endpoint of clinical response in three dose levels at week 12, with a "favorable" safety profile.
Shares of Protagonist advanced 45%, with intraday trading volume rising to over 3.9 million compared with a daily average of about 725,000.
Price: 18.23, Change: +7.71, Percent Change: +73.29
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。